Resveratrol review found pain signals but little evidence of broader benefits
Among postmenopausal women, pooled trials reported lower pain scores and a change in a bone metabolism marker, while many other outcomes showed no statistically significant effects.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review found statistically significant reductions in reported pain measures and the bone metabolism marker CTX. It did not detect significant effects across many other outcomes, including cognition, mood, blood pressure and menopausal symptoms. This pattern does not establish broad health benefits from resveratrol, and the marker change does not demonstrate fewer fractures.
The abstract does not specify treatment duration, comparator details or the units and interpretation of the pain scales. This abstract-based summary therefore cannot establish the practical size or persistence of the reported benefits.
A selective pattern of results
Pain measures favored resveratrol, but findings did not extend consistently across the other outcomes examined. Sleep disturbance, quality of life and metabolic measures also lacked statistically significant effects. Such results leave uncertainty rather than proving an absence of any effect.
Bone markers have limits
The reported reduction in CTX concerned a biological marker, while other assessed bone markers showed no significant effects. The abstract does not report fracture outcomes, so its findings cannot establish that resveratrol protects women against broken bones.
The original publication
Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis.
Wu W, Meng T, Jin F et al.
Front Pharmacol · 2025
- PubMed ID
- 40771919
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.